Prediction of short- and medium-term efficacy of biosimilar infliximab therapy. Do trough levels/antidrug antibody levels or clinical/biochemical markers play a more important role?

Gönczi, LórántVégh, ZsuzsannaGolovics, Petra AnnaRutka, MariannGecse, Krisztina B.Bor, RenátaFarkas, KlaudiaSzamosi, TamásBene, LászlóGasztonyi, BeátaKristóf, TündeLakatos, LászlóMiheller, PálPalatka, KárolyPapp, MáriaPatai, ÁrpádSalamon, ÁgnesTóth, Gábor TamásVincze, ÁronBíró, EdinaLovász, Barbara DorottyaKürti, ZsuzsannaSzepes, ZoltánMolnár, TamásLakatos, Péter2016-11-062016-11-062017Journal of Crohns & Colitis. -11 : 6 (2017), p. 697-705. -J. Crohns Colitis. - 1873-99461873-9946http://hdl.handle.net/2437/231758Prediction of short- and medium-term efficacy of biosimilar infliximab therapy. Do trough levels/antidrug antibody levels or clinical/biochemical markers play a more important role?folyóiratcikkopen access pre-print és post-printhttp://webpac.lib.unideb.hu:8082/ebib/CorvinaWeb?action=cclfind&resultview=long&ccltext=idno+BIBFORM066060OrvostudományokKlinikai orvostudományokhttps://academic.oup.com/ecco-jcc/article/11/6/697/2513724Oxford University Presshttp://dx.doi.org/10.1093/ecco-jcc/jjw2032018-04-2000040260430000685029301295